Last reviewed · How we verify
Administration of ceralasertib monotherapy
Ceralasertib is an ATP-competitive inhibitor of the serine/threonine kinase ATR, which is involved in DNA damage response pathways.
Ceralasertib is an ATP-competitive inhibitor of the serine/threonine kinase ATR, which is involved in DNA damage response pathways. Used for Advanced solid tumors.
At a glance
| Generic name | Administration of ceralasertib monotherapy |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | ATR inhibitor |
| Target | ATR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
By inhibiting ATR, ceralasertib disrupts the cellular response to DNA damage, potentially sensitizing cancer cells to genotoxic stress and enhancing the efficacy of DNA-damaging agents.
Approved indications
- Advanced solid tumors
Common side effects
- Nausea
- Fatigue
Key clinical trials
- To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. (PHASE2)
- AMTEC IIT: Phase 2 Multiarm Study in TNBC (PHASE2)
- Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (PHASE1, PHASE2)
- PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer (PHASE2)
- A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (PHASE2)
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (PHASE2)
- An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies (PHASE1)
- A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of ceralasertib monotherapy CI brief — competitive landscape report
- Administration of ceralasertib monotherapy updates RSS · CI watch RSS
- AstraZeneca portfolio CI